Dr. Ayyappan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Celebrate Life Pkwy.
Newnan, GA 30265
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 2007 - 2010
Madras Medical CollegeClass of 2004
Certifications & Licensure
GA State Medical License 2023 - 2027
IA State Medical License 2019 - 2025
OH State Medical License 2011 - 2021
MA State Medical License 2010 - 2013
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors Start of enrollment: 2005 Nov 01
- Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 Start of enrollment: 2022 Mar 17
Publications & Presentations
PubMed
- Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.Loretta J Nastoupil, Clark R Andersen, Amy Ayers, Yucai Wang, Thomas M Habermann
Clinical Lymphoma, Myeloma & Leukemia. 2025-04-01 - Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.Won Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska
Nature Cancer. 2025-03-17 - Glofitamab in patients with HIV-associated B-cell lymphoma.Jose Tinajero, Tanya Markary, Dat Ngo, Swetha Kambhampati Thiruvengadam, Sabarish Ayyappan
Leukemia & Lymphoma. 2024-12-23
Press Mentions
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
